INCY INCYTE CORP
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 879169 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.9%
TTM net income YoY-66.1%
TTM EPS YoY-66.8%
Revenue 3-yr CAGR18.5%
Net income 3-yr CAGR-1.7%
Margins
Gross margin92.7%
Operating margin10.4%
Net margin6.7%
FCF margin—
EBITDA margin12.1%
Returns
ROE7.8%
ROA5.9%
ROIC (approx.)13.9%
Asset turnover0.88x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.84x
Interest coverage267.97x
Cash quality & payout
Operating cash flow / net income1.85x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.14B | $4.24B |
| Cost of revenue | $372.13M | $312.07M |
| Gross profit | $4.77B | $3.93B |
| R&D expense | $2.05B | $2.61B |
| SG&A expense | $1.38B | $1.24B |
| Operating income | $1.51B | $61.37M |
| Interest expense | $2.43M | $2.28M |
| Pretax income | $1.66B | $316.63M |
| Income tax | $377.80M | $284.01M |
| Net income | $1.29B | $32.62M |
| EBITDA | $1.61B | $150.61M |
| EPS (basic) | 6.59 | 0.16 |
| EPS (diluted) | 6.41 | 0.15 |
| Weighted avg. shares (diluted) | 200.70M | 210.53M |
| Balance sheet | ||
| Cash & equivalents | $3.10B | $1.69B |
| Inventory | $101.06M | $58.87M |
| Current assets | $5.02B | $3.24B |
| PP&E, net | $730.88M | $763.41M |
| Goodwill | $133.00M | $155.59M |
| Total assets | $6.96B | $5.44B |
| Current liabilities | $1.52B | $1.64B |
| Total liabilities | $1.79B | $2.00B |
| Shareholders' equity | $5.17B | $3.45B |
| Shares outstanding | 198.46M | 193.43M |
| Cash flow statement | ||
| Operating cash flow | $1.41B | $335.34M |
| Investing cash flow | -$102.61M | $157.52M |
| Financing cash flow | $101.04M | -$2.02B |
| Depreciation & amortization | $93.29M | $89.25M |
| Stock-based compensation | $249.35M | $266.06M |
| Share buybacks | $0 | $2.00B |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.